Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, HER2 (ERBB2) — the founding precision oncology target since Trastuzumab approval in 1998 — has matured into one of the most clinically active and commercially valuable solid tumor targets globally, with 981 active drug programs, over 4,000 patent filings since January 2023, and 1,755 ongoing Phase 2 and Phase 3 trials. Notably, the field is anchored by Daiichi Sankyo/AstraZeneca’s Enhertu (Trastuzumab Deruxtecan) plus a multi-modality competitive arena spanning monoclonal…
Author: Eureka LS
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, triple-Negative Breast Cancer (TNBC) — the most aggressive breast cancer subtype lacking ER, PR, and HER2 expression — has been transformed from a chemotherapy-only disease into a multi-mechanism precision oncology arena, with 1,470 active drug programs, 2,082 patent filings since January 2023, and 754 ongoing Phase 2 and Phase 3 trials. Notably, the field is anchored by Gilead/Immunomedics’s Trodelvy (Sacituzumab govitecan, TROP2 ADC, FDA approval 2020), Merck’s Keytruda (pembrolizumab…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, tyrosine Kinase 2 (TYK2) — a JAK-family kinase mediating IL-23, IL-12, and Type I interferon signaling — has emerged as the most strategically active oral immunology target since Bristol Myers Squibb’s Deucravacitinib (Sotyktu) FDA approval in September 2022, with 142 active drug programs, over 335 patent filings since January 2023, and 186 ongoing Phase 2 and Phase 3 trials. Notably, Sotyktu’s allosteric pseudokinase-binding mechanism avoids JAK1/2/3 cross-reactivity, enabling oral…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, pancreatic cancer — historically one of the most clinically challenging oncology indications with a 5-year survival rate below 13% — has crossed into a precision-medicine era anchored by 2,847 active drug programs, 13,646 patent filings since January 2023, and 2,022 ongoing Phase 2 and Phase 3 trials. Notably, KRAS G12D mutation occurs in approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases, positioning Astellas’s Setidegrasib (KRAS G12D PROTAC, Phase 3)…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, histone Deacetylase (HDAC) inhibitors have evolved from a single-mechanism oncology class anchored by Vorinostat (Merck, 2006) into a multi-isoform, multi-indication platform spanning hematology, solid tumors, and emerging neurology applications. Notably, the 2026 landscape captures 956 active HDAC drug programs, 2,318 patent filings since January 2023, and 869 ongoing Phase 2 and Phase 3 trials. Specifically, the late-stage competitive frontier is segmenting into four strategic lanes: (1) approved pan-HDAC inhibitors…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, fibroblast Activation Protein (FAP) — a serine protease overexpressed on cancer-associated fibroblasts in over 90% of epithelial tumors — has emerged as one of the most clinically active theranostic targets globally, with 330 active drug programs, 1,252 patent filings since January 2023, and 44 ongoing Phase 2 and Phase 3 trials. Notably, no FAP-targeted therapy has yet received regulatory approval, leaving the entire field in pre-commercial competitive positioning despite…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, respiratory Syncytial Virus (RSV) — historically managed only with Palivizumab (1998) and supportive care — has been transformed into one of the most active commercial respiratory franchises since 2023, with 391 active drug programs, 458 patent filings since January 2023, and 209 ongoing Phase 2 and Phase 3 trials. Notably, the 2023-2025 wave of approvals — GSK’s Arexvy (May 2023), Pfizer’s Abrysvo / RSVpreF (January 2023), Sanofi/AstraZeneca’s Beyfortus /…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, osteoporosis has matured into a multi-mechanism therapeutic area anchored by long-acting biologics (Denosumab, Romosozumab) plus established generic bisphosphonates, with 661 active drug programs, 3,040 patent filings since January 2023, and 552 ongoing Phase 2 and Phase 3 trials. Notably, the field captures 200 sampled drug programs spanning 128 small molecule drugs, 10 synthetic peptides, 10 herbal medicines, 9 monoclonal antibodies, 8 peptide hormones, and 6 biological products. Specifically, the…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) — a Wnt5a co-receptor selectively expressed on multiple hematologic malignancies and solid tumors but minimally expressed on normal adult tissues — has emerged as one of the most strategically active oncology targets, with 134 active drug programs, 914 patent filings since January 2023, and 11 ongoing Phase 2 and Phase 3 trials. Notably, no ROR1-targeted therapy has yet received regulatory approval, leaving…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, TP53 (p53) — the most frequently mutated gene in human cancer (over 50% of all malignancies) — has remained one of the most challenging “undruggable” oncology targets for over three decades, with 281 active drug programs, 2,440 patent filings since January 2023, and 79 ongoing Phase 2 and Phase 3 trials. Notably, only adenovirus-based gene therapies (Recombinant Human Ad-p53 / Gendicine) have achieved regulatory approval (China NMPA 2003-2005), while…